Expert Council Resolution “The place of quifenadine in the treatment of allergic diseases and the classification of antihistamines”

N.M. Nenasheva, N.I. Ilyina, I.S. Gushchin, I.V. Danilycheva, I.N. Zakharova, S.K. Zyryanov, O.M. Kurbacheva, Yu.S. Smolkin, E.A. Orlova, D.A. Sychev

1) Russian Medical Academy of Continuous Professional Education, Moscow, Russia; 2) State Research Center “Institute of Immunology” of the Federal Medical and Biological Agency, Moscow, Russia; 3) Peoples’ Friendship University of Russia, Moscow, Russia; 4) Federal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency, Moscow, Russia; 5) Penza Institute for Postgraduate Medical Education – a Branch Campus of the Russian Medical Academy of Continuous Professional Education, Penza, Russia

Antihistamines are the most commonly prescribed pharmacological therapy for allergic diseases, the prevalence of which reaches 30% of the population in the modern world, affecting people of all ages. The appointment of antihistamines for allergic rhinitis and urticaria is the first line of therapy, allowing in most cases to achieve control of symptoms. Existing antihistamines are usually divided into I and II generation antihistamines. Hifenadine, synthesized in the Acad. M.D. Mashkovsky laboratory in the 1970s, was historically assigned to the 1st generation antihistamines, however, according to its characteristics (low risk of sedation, absence of tachyphylaxis, antiserotonin effect, activation of diamine oxidase), it rather belongs to the 2nd generation antihistamines. This discrepancy raises questions and may confuse clinicians when prescribing the drug. In this regard, an Expert Council with the purpose to define the pharmacological properties of hifenadine, its clinical efficacy, tolerability and safety, which determine the place of the drug in the classification of antihistamines and the treatment of allergic diseases was held.

Keywords

About the Authors

Corresponding author: Natalya M. Nenasheva, Dr. Sсi. (Med.), Professor, Head of the Department of Allergology and Immunology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; 1444031@gmail.com; Scopus Author ID: 57201763856

Similar Articles